Cristiana M.
- Country
- Portugal
- Department
- Medical Oncology Department
Research Overview
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- Phase III Randomized Study of Camizestrant and CDK4/6 Inhibitor Versus Aromatase Inhibitor and CDK4/6 Inhibitor in HR+/HER2- Advanced Breast Cancer with ESR1 Mutation
- Efficacy and Safety of RLY-2608 Plus Fulvestrant Versus Capivasertib Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
Data & Insights
Has run more than one trial at 144 of 424 partner sites.
Specializations
Breast Cancer Treatment Innovation
This investigator specializes in developing advanced therapeutic approaches for estrogen receptor-positive (ER+) breast cancer, with particular emphasis on HER2-negative breast cancer variants.
- Early-stage breast cancer management
- Extended adjuvant therapy protocols
- Advanced disease treatment strategies
The research focus includes novel endocrine therapy applications in both early and advanced disease settings.
Targeted Therapeutic Development
The investigator's work centers on evaluating innovative targeted therapies, particularly selective estrogen receptor degraders and their combination with established treatments.
- Endocrine therapy optimization
- Combined therapeutic approaches
- Treatment resistance management
Their research encompasses both monotherapy and combination treatment strategies for hormone-responsive breast cancer.
Precision Medicine Applications
The investigator explores personalized treatment approaches, particularly in cases involving ESR1 mutations and specific molecular subtypes of breast cancer.
- Biomarker-driven treatment selection
- Molecular targeting strategies
- Treatment response optimization
Their work focuses on tailoring treatments based on specific molecular characteristics of breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.